PDPN and cancer: Despite the specific labeling of the lymphatic endothelium, cancer cells as well as dendritic cells and especially cancer-associated fibroblasts (CAFs) express podoplanin to varying degrees—with poor clinical prognosis in case of high-rates CAFs within pulmonary adenocarcinoma as well as invasive breast cancers and a distinct relation with patient clinical outcome in case of tumoral D2-40 expression on cancer cells6–11.